Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)

Open to males ages 18 years and up

1. Patient is male and aged >18 years old.
2. History of localized adenocarcinoma of the prostate with prior curative intent treatment.
3. An elevated PSA, clinically suspicious for biochemically recurrent disease:
4. Following Radical Prostatectomy: PSA >0.2 ng/mL
5. Following Radiotherapy: nadir +2 ng/mL.
6. Potentially eligible for salvage therapy with curative intent.

1. Patients who are planned to have an x-ray contrast agent or other PET radiotracer <24 hours prior to the PET scan.
2. Patients currently receiving Androgen Deprivation Therapy (ADT).